Managing cancer-related anaemia with epoetin alfa

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 1, 2002, Pages 73-77

  Itri, Loretta M ^a  

^a Genta Incorporated   (United States)

Author keywords

Anaemia; Cancer; Epoetin alfa; Haemoglobin; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER; CANCER PATIENT; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HEMATOCRIT; HUMAN; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; VERTIGO;

EID: 0036175164     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_1.73     Document Type: Article

References (9)

1. Decreased erythropoietin response in patients with anemia of cancer
2. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy
3. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin
4. Erythropoietin for anaemia in cancer patients
5. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
6. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
7. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing
8. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects
9. Effects of epoetin alfa on hematological parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized double-blind, placebo-controlled trial